Episode Details
Back to Episodes
Duopharma Seeking To Diversify Manufacturing Domain
Published 2 years, 6 months ago
Description
Malaysian pharmaceutical Duopharma Biotech achieved their best financial performance to date in 2022, reaching record highs for revenue and profit. However 2023 was not as kind, with profit after tax falling by 25% despite top line growth. How are they looking to reverse course in 2024? We discuss strategy with Group Managing Director Leonard Ariff Abdul Shatar.
See omnystudio.com/listener for privacy information.